Battrion develops and markets its Aligned Graphite Technology (AGT) to decrease the charging time of lithium-ion batteries by up to 50%. Its co-founder Martin Ebner, who held the CEO position since 2015 has assumed the role of CTO, leaving the CEO chair to Markus Vollstedt, an economist by profession. Vollstedt brings significant experience in management, sales, and finance, especially in young and fast-growing companies. He has previously founded, developed and sold businesses, and currently, invests in tech companies. With him and his experience, Battrion has strengthened and diversified responsibilities of its management team, which is completed by Max Kory (COO). The former CTO Deniz Bozyigit will concentrate on his role as Board Member to support the company on strategic and technological topics.
Role change at Versameb
Versameb, a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, has appointed Klaas Zuideveld as CEO. Zuideveld succeeds Friedrich Metzger who will take over the role of Chief Scientific Officer (CSO) to develop Versameb's innovative platform to enhance and combine therapeutic protein expression and cellular targeting, optimizing and tailoring first-in-class RNA therapeutics for hard to treat diseases. RNA is one of the four major macromolecules essential for all known forms of life.
The new CEO brings over 20 years of drug development and life science industry experience to Versameb at a pivotal stage in its growth as two of its lead assets transition from early discovery into clinical development. Klaas joined Versameb as Chief Development Officer in May 2020. Prior to this, Klaas has held leadership positions at Roche where he has led the clinical development of Avastin (bevacizumab).
Three appointments at Virometix
Virometix is a biotech company developing a new generation of vaccines and immunotherapeutic drugs to prevent and treat infectious and oncology diseases. The company has expanded its leadership team with Lilli Stergiou as Chief Scientific Officer, and Susanne Schultz-Hector and Jan ter Meulen as Board members.
Lilli Stergiou has 20 years of research and development experience in multiple fields including all areas of interest to Virometix – vaccines, infectious diseases, and oncology. She joins Virometix from Redbiotec AG, where she was CSO, headed the HSV-2 Therapeutic Vaccine Program and built a pipeline based on live biotherapeutics for applications in oncology.
Susanne Schultz-Hector is an independent university lecturer and member of various boards. She has deep experience in radiation biology and has published 27 original papers as first or corresponding author in international, peer-reviewed journals. She conducted research both in Germany and in the USA
Jan ter Meulen is a seasoned biotech executive with broad experience in immuno‐oncology, vaccines, recombinant antibodies, and infectious disease R&D, from discovery research to phase 3 clinical trials. His career spans over various academic and business functions, including Crucell and Merck & Co, where he headed basic vaccine research.
Photo: L-R:Markus Vollstedt, Klaas Zuideveld, Lilli Stergiou and Jan ter Meulen